CommercialCoverageMedium impact
Genetic Testing for Thoracic Aortic Aneurysms/ Dissections and Connective Tissue Related Disorders 2.02.61
Excellus BlueCross BlueShield·Cardiology, Cardiothoracic Surgery, Vascular Surgery +3 more·Genetic Disease (Inherited Disease)
Effective date
Jan 15, 2026
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield updated their genetic testing policy for thoracic aortic aneurysms and connective tissue disorders, establishing specific criteria for when genetic testing is considered medically necessary. The policy covers testing for Ehlers-Danlos syndrome, Marfan syndrome, Loeys-Dietz syndrome, and thoracic aortic aneurysm disorders with detailed clinical criteria.
Action Required
By January 15, 2026: Billing team must review genetic testing requests for thoracic aortic aneurysms and connective tissue disorders to ensure they meet the specific clinical criteria outlined in policy 2.02.61. Update prior authorization workflows to verify patients meet the documented major/minor criteria before submitting genetic testing claims. Ensure genetic counseling documentation is included with all test requests as this is required for coverage.